The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $6.56 billion in 2025 to $7.48 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to success of early car-t therapies, unmet oncology needs, research funding growth, regulatory approvals, academic-industry collaboration.
The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $12.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to expansion into solid tumors, innovation in nk cell therapy, scalable manufacturing technologies, supportive regulatory frameworks, increased oncology investment. Major trends in the forecast period include rapid growth of car-t cell therapies, expansion of allogeneic cell therapies, increasing use in hematologic malignancies, advancements in t cell engineering, rising clinical trial activity.
The increasing prevalence of cancer is expected to drive the expansion of the cellular immunotherapy market in the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to an aging population, lifestyle choices, and advancements in screening and diagnosis. Environmental exposures and genetic predispositions also significantly contribute to the increasing incidence. Cellular immunotherapy enhances the immune system's response against cancer by specifically targeting tumor cells, thereby improving survival rates. When used alongside other treatments, this approach may contribute to a reduction in cancer incidence and recurrence. For example, in March 2024, MAC Clinical Research, a UK-based cancer research organization, reported that the estimated number of people living with cancer in the United Kingdom is expected to rise from around 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is propelling the growth of the cellular immunotherapy market.
Major companies operating in the cellular immunotherapy market are concentrating on developing technological innovations such as immunotherapy to improve treatment effectiveness and broaden its applications. Their focus areas include personalized medicine, combination therapies, and scalable manufacturing to enhance patient outcomes. Immunotherapy is a treatment that leverages the body’s immune system to combat diseases, particularly cancer. It may involve enhancing immune responses or delivering targeted therapies to boost immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, highlighted CAR-T cell therapy, a groundbreaking cancer treatment that uses genetically engineered T cells to precisely target and eliminate cancer cells, offering a personalized strategy. This therapy provides long-lasting remission rates, especially for treatment-resistant blood cancers, while minimizing harm to healthy tissues.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. Through this acquisition, AstraZeneca intends to strengthen its oncology portfolio and accelerate the development of innovative T-cell receptor therapies for solid tumors via Neogene Therapeutics. Neogene Therapeutics, Inc., a US-based biotechnology firm, specializes in personalized cellular immunotherapy, engineering T-cells to specifically target cancer cells.
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation.
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have raised the cost of imported cell therapy equipment, single use systems, and specialized reagents used in advanced therapy manufacturing. These impacts are most evident in Europe and Asia, where cell therapy developers rely on cross border sourcing for critical inputs. Rising tariff related expenses have increased production costs and influenced investment planning for cell based therapies. This has affected scale up timelines and capacity expansion decisions. However, tariffs are also encouraging regional manufacturing capabilities, local supplier ecosystems, and greater self sufficiency in advanced therapy production over the long term.
The cellular immunotherapy market research report is one of a series of new reports that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cellular immunotherapy is a type of immunotherapy in which a patient is given T cells, a type of immune cell, to help the body fight diseases such as cancer. It is an advanced form of treatment that harnesses the body's immune system to target cancer.
The main therapies in cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy that involves isolating lymphocytes that have infiltrated tumors, expanding and culturing them in vitro, and then reintroducing them into patients for treatment. The primary indications include B-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and it is applied in the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and additional types of cancer.
The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $12.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to expansion into solid tumors, innovation in nk cell therapy, scalable manufacturing technologies, supportive regulatory frameworks, increased oncology investment. Major trends in the forecast period include rapid growth of car-t cell therapies, expansion of allogeneic cell therapies, increasing use in hematologic malignancies, advancements in t cell engineering, rising clinical trial activity.
The increasing prevalence of cancer is expected to drive the expansion of the cellular immunotherapy market in the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to an aging population, lifestyle choices, and advancements in screening and diagnosis. Environmental exposures and genetic predispositions also significantly contribute to the increasing incidence. Cellular immunotherapy enhances the immune system's response against cancer by specifically targeting tumor cells, thereby improving survival rates. When used alongside other treatments, this approach may contribute to a reduction in cancer incidence and recurrence. For example, in March 2024, MAC Clinical Research, a UK-based cancer research organization, reported that the estimated number of people living with cancer in the United Kingdom is expected to rise from around 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is propelling the growth of the cellular immunotherapy market.
Major companies operating in the cellular immunotherapy market are concentrating on developing technological innovations such as immunotherapy to improve treatment effectiveness and broaden its applications. Their focus areas include personalized medicine, combination therapies, and scalable manufacturing to enhance patient outcomes. Immunotherapy is a treatment that leverages the body’s immune system to combat diseases, particularly cancer. It may involve enhancing immune responses or delivering targeted therapies to boost immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, highlighted CAR-T cell therapy, a groundbreaking cancer treatment that uses genetically engineered T cells to precisely target and eliminate cancer cells, offering a personalized strategy. This therapy provides long-lasting remission rates, especially for treatment-resistant blood cancers, while minimizing harm to healthy tissues.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. Through this acquisition, AstraZeneca intends to strengthen its oncology portfolio and accelerate the development of innovative T-cell receptor therapies for solid tumors via Neogene Therapeutics. Neogene Therapeutics, Inc., a US-based biotechnology firm, specializes in personalized cellular immunotherapy, engineering T-cells to specifically target cancer cells.
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation.
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have raised the cost of imported cell therapy equipment, single use systems, and specialized reagents used in advanced therapy manufacturing. These impacts are most evident in Europe and Asia, where cell therapy developers rely on cross border sourcing for critical inputs. Rising tariff related expenses have increased production costs and influenced investment planning for cell based therapies. This has affected scale up timelines and capacity expansion decisions. However, tariffs are also encouraging regional manufacturing capabilities, local supplier ecosystems, and greater self sufficiency in advanced therapy production over the long term.
The cellular immunotherapy market research report is one of a series of new reports that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cellular immunotherapy is a type of immunotherapy in which a patient is given T cells, a type of immune cell, to help the body fight diseases such as cancer. It is an advanced form of treatment that harnesses the body's immune system to target cancer.
The main therapies in cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy that involves isolating lymphocytes that have infiltrated tumors, expanding and culturing them in vitro, and then reintroducing them into patients for treatment. The primary indications include B-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and it is applied in the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and additional types of cancer.
The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cellular Immunotherapy Market Characteristics
3. Cellular Immunotherapy Market Supply Chain Analysis
4. Global Cellular Immunotherapy Market Trends and Strategies
5. Cellular Immunotherapy Market Analysis of End Use Industries
7. Global Cellular Immunotherapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cellular Immunotherapy Total Addressable Market (TAM) Analysis for the Market
9. Cellular Immunotherapy Market Segmentation
10. Cellular Immunotherapy Market Regional and Country Analysis
11. Asia-Pacific Cellular Immunotherapy Market
12. China Cellular Immunotherapy Market
13. India Cellular Immunotherapy Market
14. Japan Cellular Immunotherapy Market
15. Australia Cellular Immunotherapy Market
16. Indonesia Cellular Immunotherapy Market
17. South Korea Cellular Immunotherapy Market
18. Taiwan Cellular Immunotherapy Market
19. South East Asia Cellular Immunotherapy Market
20. Western Europe Cellular Immunotherapy Market
21. UK Cellular Immunotherapy Market
22. Germany Cellular Immunotherapy Market
23. France Cellular Immunotherapy Market
24. Italy Cellular Immunotherapy Market
25. Spain Cellular Immunotherapy Market
26. Eastern Europe Cellular Immunotherapy Market
27. Russia Cellular Immunotherapy Market
28. North America Cellular Immunotherapy Market
29. USA Cellular Immunotherapy Market
30. Canada Cellular Immunotherapy Market
31. South America Cellular Immunotherapy Market
32. Brazil Cellular Immunotherapy Market
33. Middle East Cellular Immunotherapy Market
34. Africa Cellular Immunotherapy Market
36. Cellular Immunotherapy Market Competitive Landscape and Company Profiles
37. Cellular Immunotherapy Market Other Major and Innovative Companies
40. Cellular Immunotherapy Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cellular Immunotherapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cellular immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cellular immunotherapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cellular immunotherapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy; Engineered T Cell Receptor (TCR) Therapy; Chimeric Antigen Receptor (CAR) T Cell Therapy; Natural Killer (NK) Cell Therapy2) By Primary Indication: B-cell Malignancies; Prostate Cancer; Renal Cell Carcinoma; Liver Cancer; Non-Hodgkin lymphoma; Other Primary Indications
3) By Application: Prostate Cancer; Breast Cancer; Skin Cancer; Ovarian Cancer; Brain Tumor; Lung Cancer; Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy; Allogeneic TIL Therapy2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy; Gamma-Delta TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy; Allogeneic CAR T Cell Therapy; CAR T Cell Therapy For Solid Tumors; CAR T Cell Therapy For Hematologic Malignancies
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy; Allogeneic NK Cell Therapy; NK Cell Therapy With Engineered Modifications
Companies Mentioned: Novartis International AG; Gilead Sciences Inc.; Apac Biotech; Dendreon Pharmaceuticals LLC; JW CreaGene Co. Ltd; Green Cross Corp; AstraZeneca plc; Bristol Myers Squibb Company; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Adicet Bio Inc.; ResTORbio Inc.; Celyad SA; Merck KGaA; GlaxoSmithKline plc.; Johnson & Johnson; Adaptimmune Therapeutics plc; AVROBIO Inc.; Cellular Biomedicine Group Inc.; Kite Pharma Inc.; Juno Therapeutics Inc.; Celgene Corporation; Bluebird Bio Inc.; Tmunity Therapeutics Inc.; Atara Biotherapeutics Inc.; Fate Therapeutics Inc.; Precision Biosciences Inc.; Allogene Therapeutics Inc.; CRISPR Therapeutics AG; Sangamo Therapeutics Inc.; Intellia Therapeutics Inc.; Editas Medicine Inc.; Caribou Biosciences Inc.; Mammoth Biosciences Inc.; Synthego Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cellular Immunotherapy market report include:- Novartis International AG
- Gilead Sciences Inc.
- Apac Biotech
- Dendreon Pharmaceuticals LLC
- JW CreaGene Co. Ltd
- Green Cross Corp
- AstraZeneca plc
- Bristol Myers Squibb Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Adicet Bio Inc.
- ResTORbio Inc.
- Celyad SA
- Merck KGaA
- GlaxoSmithKline plc.
- Johnson & Johnson
- Adaptimmune Therapeutics plc
- AVROBIO Inc.
- Cellular Biomedicine Group Inc.
- Kite Pharma Inc.
- Juno Therapeutics Inc.
- Celgene Corporation
- Bluebird Bio Inc.
- Tmunity Therapeutics Inc.
- Atara Biotherapeutics Inc.
- Fate Therapeutics Inc.
- Precision Biosciences Inc.
- Allogene Therapeutics Inc.
- CRISPR Therapeutics AG
- Sangamo Therapeutics Inc.
- Intellia Therapeutics Inc.
- Editas Medicine Inc.
- Caribou Biosciences Inc.
- Mammoth Biosciences Inc.
- Synthego Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.48 Billion |
| Forecasted Market Value ( USD | $ 12.5 Billion |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 36 |
